Almost Family Inc (AFAM) 44.07 $AFAM Almost Family, Inc.

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 11:20 PM

Almost Family Inc (AFAM) 44.07 $AFAM

Almost Family, Inc. to Present at the Jefferies Healthcare Conference
GlobeNewswire - Tue Jun 07, 7:32AM CDT
Almost Family, Inc. (Nasdaq:AFAM), a leading regional provider of home health nursing and personal care services, announced today that Steve Guenthner, President and Principal Financial Officer is scheduled to present at the Jefferies Healthcare Conference in New York City.
AFAM: 44.07 (-0.32)

Almost Family Announces Home Health Entry into The State of Wisconsin
GlobeNewswire - Wed May 25, 7:30AM CDT
Almost Family, Inc. (NASDAQ:AFAM), today announced that it has entered into a transaction for entry into the State of Wisconsin through the acquisition of certain home health agency assets from ResCare Inc. Annualized revenues of $15 million, principally for personal care services, are expected to be generated across 8 branches in Wisconsin.
AFAM: 44.07 (-0.32)

DaVita to Expand in Orlando with Family Health Care Buyout
Zacks Equity Research - Zacks Investment Research - Mon May 23, 3:07PM CDT
DaVita Healthcare Partners (DVA) has entered into a definitive agreement to acquire Family Health Care of Central Florida to expand its presence in Orlando metro area.
PMC: 25.91 (+0.27), AFAM: 44.07 (-0.32), DVA: 78.44 (+0.37), HLS: 40.18 (+0.45)

Quest Diagnostics (DGX) Divests Focus, Cuts Sales View
Zacks Equity Research - Zacks Investment Research - Thu May 19, 5:44AM CDT
Quest Diagnostics Inc. (DGX) has updated its outlook for 2016 following the completion of the sale of Focus Diagnostics Inc.
AFAM: 44.07 (-0.32), LHCG: 45.89 (+0.36), DGX: 82.82 (+0.59), HLS: 40.18 (+0.45)

BioScrip (BIOS) Q1 Loss Wider than Expected, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:11AM CDT
BioScrip, Inc. (BIOS) reported net loss from continuing operations of 17 cents per share in the first quarter of 2016.
USPH: 62.25 (unch), AFAM: 44.07 (-0.32), BIOS: 2.64 (-0.05), HLS: 40.18 (+0.45)

Almost Family, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
GlobeNewswire - Mon May 09, 8:14AM CDT
Almost Family, Inc. (Nasdaq:AFAM), a leading regional provider of home health nursing and personal care services, announced today that Steve Guenthner, President and Principal Financial Officer is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada.
AFAM: 44.07 (-0.32)

Amedisys (AMED) Lags Q1 Earnings, Revenues Top the Mark
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:56AM CDT
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 33 cents per share in the first quarter of 2016.
BSX: 23.77 (-0.13), AFAM: 44.07 (-0.32), AMED: 52.25 (-0.08), HLS: 40.18 (+0.45)

Almost Family Reports First Quarter 2016 Results
GlobeNewswire - Wed May 04, 6:30AM CDT
Almost Family, Inc. (Nasdaq:AFAM), a leading regional provider of home health nursing and personal care services, announced today its financial results for the quarter ended April 1, 2016.
AFAM: 44.07 (-0.32)

Almost Family, Inc. to Report First Quarter 2016 Financial Results on May 4, 2016
GlobeNewswire - Mon May 02, 6:18PM CDT
Almost Family, Inc. (Nasdaq:AFAM), a leading regional provider of home health nursing and personal care services, announced today that it will report financial results for its first quarter 2016 on Wednesday, May 4, 2016, publishing an earnings release before the market opens.
AFAM: 44.07 (-0.32)

Chemed (CHE) Q1 Earnings Miss the Mark, Revenues in Line
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:53AM CDT
Chemed Corp. (CHE) reported first-quarter 2016 adjusted earnings per share (EPS) of $1.53.
CHE: 137.91 (+0.43), AFAM: 44.07 (-0.32), AMED: 52.25 (-0.08), HLS: 40.18 (+0.45)

Quest Diagnostics (DGX) Q1 Earnings in Line, Volume Up
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:23AM CDT
Quest Diagnostics' (DGX) first-quarter 2016 adjusted earnings per share (EPS) of $1.12 came in line with the Zacks Consensus Estimate.
BSX: 23.77 (-0.13), AFAM: 44.07 (-0.32), DGX: 82.82 (+0.59), AMED: 52.25 (-0.08)

AmSurg Poised on Strategic Buyouts, Rising Costs a Concern
Zacks Equity Research - Zacks Investment Research - Wed Apr 20, 4:46PM CDT
On Apr 18, 2016, we issued an updated research report on Nashville, TN-based AmSurg Corp. (AMSG).
AMSG: 79.73 (+1.07), BSX: 23.77 (-0.13), AFAM: 44.07 (-0.32), AMED: 52.25 (-0.08)

3 Reasons Value Stock Investors Will Love Almost Family (AFAM)
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 8:16AM CDT
Almost Family looks great given its impressive metrics and estimate revisions
AFAM: 44.07 (-0.32)

Amedisys Poised on Balanced Growth, Strategic Buyouts
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 1:35PM CDT
On Apr 11, 2016, we issued an updated research report on Amedisys Inc. (AMED).
AFAM: 44.07 (-0.32), CSII: 19.32 (-0.30), RMD: 64.28 (-0.23), AMED: 52.25 (-0.08)

DaVita to Acquire Mountain View, Expand Footprint in Colorado
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 1:35PM CDT
DaVita HealthCare Partners Inc. (DVA) intends to acquire Mountain View Medical Group to enhance its kidney care services and extend footprint in Colorado Springs.
ABUS: 3.99 (+0.08), AFAM: 44.07 (-0.32), DVA: 78.44 (+0.37), AMED: 52.25 (-0.08)

Strength Seen in Amedisys (AMED): Stock Soars 14.7%
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 7:00AM CST
Amedisys (AMED) was a big mover last session with its shares rising roughly 15% on the day.
AFAM: 44.07 (-0.32), AMED: 52.25 (-0.08)

3 Cheap Growth Stocks You Can Buy Right Now
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 10, 6:03AM CST
Image source: StockMonkeys.com via Flickr. When the stock market was in nearly nonstop rally mode for most of the past six years, investors didn't need to look far to uncover an abundance of growth stocks. But not all growth stocks are created...
CAL: 26.43 (+1.00), BIDU: 167.03 (+7.23), AFAM: 44.07 (-0.32)

DaVita Closes Everett Buyout, Continues Inorganic Growth
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 2:55PM CST
DaVita HealthCare Partners (DVA) announced the timely completion of its acquisition of The Everett Clinic.
HCA: 78.16 (-0.05), AFAM: 44.07 (-0.32), DVA: 78.44 (+0.37)

New Strong Buy Stocks for February 9th
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
AGTC: 15.97 (+0.16), ACHC: 54.46 (+0.61), ACAS: 15.90 (+0.04), AFAM: 44.07 (-0.32), ADSK: 55.49 (+0.35)

Almost Family, Citigroup and GoPro, highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 8:30AM CST
Almost Family, Citigroup and GoPro, highlighted as Zacks Bull and Bear of the Day
GPRO: 12.43 (+1.46), AFAM: 44.07 (-0.32), C: 42.29 (+0.31)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Giese Foundation Boosts Cancer Support Services Reach

When cancer pays an unwelcome visit to a family, it doesn’t come alone. It drags along fear, uncertainty, and bruising challenges. And as support needs balloon, thankfully there's a beacon like the Brian & Patricia Giese Foundation stepping up to sustain vital programs. Understanding the Real Impact Now, listen up. Cancer may target one body, but its claws reach...

Gillis Joins McGinnis Lochridge as COO Amid Firm's Milestone

An Experienced Executor at the Helm Now, here's a story that rings of continuity meeting change. McGinnis Lochridge, a staple of the Texas legal scene since 1927, has tapped Charles Gillis to take charge as their Chief Operating Officer. You'd think they're gearing up to celebrate a hundred years by shaking things up internally. Why not bring in someone seasoned, I say?...

InfraMed Expands Team for National Healthcare Growth

InfraMed's Bold Move in Healthcare Real Estate You know, it’s not every day you see a company go all in on healthcare properties like InfraMed’s doing. With the blitz of new personnel, we're talking about a genuine push to carve out a piece of the national market. And if you've been keeping tabs, this isn't just a hunch—they've got serious momentum brewing, and the...

Roofr Unveils AI Tools: Shaping Roofing's Future

Making Waves in Roofing: Roofr's Big Moves Listen up, folks. When a company like Roofr announces new tech, contractors better pay attention. The roofing industry—often overlooked by the flashy tech scene—just got hit with some slick new tools. Today, Roofr held its semi-annual virtual event, Roofr Builds, unraveling a slew of updates that might just streamline the way...

Escalade to Unveil Q3 2026 Results and Host Call

Details on Escalade's Upcoming Financial Revelation Evansville's own Escalade, Inc. (NASDAQ: ESCA) is set to drop its third quarter 2026 financial results on October 29, well before your breakfast is done. For anyone following this stock, it's like waiting for the last few seconds of a tied basketball game. This isn’t just about numbers – it’s about a whole host of...

Green Builder Media's Fresh Focus on Net Zero Homes

There's a fresh breeze blowing through the building industry, and it's got "net zero" written all over it. Green Builder Media is rolling out a pile of new resources aimed at wrangling this beast of a trend. The focus? High-performance, all-electric homes. And they're not just whispering about it—they've got hard data and practical guidance to back up their claims. Net...

OTconnect on Apple Watch: A New Fitness Era Dawns

What’s Orangetheory Up To Now? Ah, fitness gadgets, where everyone’s seemingly got a scheme brewing. This time it's Orangetheory (OTF), turning your Apple Watch into your new best gym buddy. October 22, 2026, marks the launch of OTconnect for Apple Watch, offering a slick way for enthusiasts to tune into their own sweat metrics. If you’re already an Apple Watch...

US Myeloma Network Revolutionizes Cancer Trials in U.S.

New Era for Myeloma Research In a move set to shake up the oncology world, the International Myeloma Foundation (IMF) is lighting a fire under clinical research with its ambitious US Myeloma Network (USMN). The whole shebang is about supercharging clinical trials and bringing real hope to folks battling multiple myeloma. If you've been watching the space, you know we're...

Rising Demand for Natural Fibres: Woolmark's Bold Move

A Shift Toward Nature-Driven Choices There's something brewing in the fashion world that signals a deeper shift—a movement toward fibers that feel real, fibers that nature and time have refined. Recent Ipsos research commissioned by Woolmark has laid bare the growing consumer preference across major markets, with a distinct swing towards natural fibers, leaving...

Fort Point Capital Sells AMS Fulfillment to Stord

Fort Point Capital's Strategic Play Just when you thought the game was getting stale, Fort Point Capital dropped a bomb: they’ve sold AMS Fulfillment to Stord. This isn't just some late-season punt; it's a calculated play from a Boston-based private equity player known for snapping up and scaling service-oriented businesses in the lower middle market. It's like...